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Summary Using an 'intelligent' tablet bottle which, unknown to the patient, electronically records the
times of opening we have assessed the compliance of patients with prescribed oral medication. The compliance
pattern of 12 patients receiving low dose etoposide for small cell lung cancer was monitored over 25 treatment
periods, representing a total of 298 days. The data were expressed as overall compliance (OC), defined as the
observed number of bottle openings as a percentage of the prescribed number of doses, and as two indices
representing daily and hourly irregularities in the times of opening. The OC had a mean (± s.d.) value of
93.2% (± 12%) over the 25 treatment periods, and is similar to that which we have reported in a group of
lymphoma patients (Lee et al., 1992). By means of a self assessed diary card we monitored the physical and
mental state of the patients. Although we found significant associations between the compliance measures and
some of the diary card measures, the magnitude of the observed effects would be of little practical conse-
quence. We conclude that, in our group of patients, inadequate compliance with oral chemotherapy would not
account for any significant lack of clinical response.
Compliance with oral cancer chemotherapy has not been
extensively studied. The studies of Levine et al. (1987), in
patients with haematological malignancies, and of Lebovits et
al. (1990), in patients with breast cancer both showed surpris-
ingly low levels of compliance. In view of the uncertainties
implicit in compliance assessment we developed a novel tech-
nique employing an 'intelligent' tablet bottle which, unknown
to the patient, electronically records the times of opening.
Using this device in a group of lymphoma patients (Lee et
al., 1992) we showed high rates of compliance. However this
excellent compliance may have been associated with the good
prognosis for lymphoma and with treatments which were not
particularly toxic. The present study therefore uses the same
methodology to assess compliance in patients having a poor
prognosis and taking medication likely to cause unpleasant
side effects.
There is evidence (Slevin, 1990) that low dose etoposide
regimes yield response rates in advanced small cell lung
cancer equivalent to those obtained with conventional in-
travenous chemotherapy. Newer schedules giving low-dose
etoposide over 14-21 days (Einhorn, 1991; Greco et al.,
1991) require oral dosing allowing less hospitalisation and
less inconvenience for the patient.
We report here a study on the compliance with low dose
oral etoposide therapy in out-patients receiving palliative
treatment for relapsed or poor performance status small cell
lung cancer. The method of compliance assessment using the
electronically monitored tablet bottle enables continuous
monitoring, unknown to the patient. It reveals information
about the pattern, as well as the total number, of bottle
openings. The physical and mental state of the patients was
self-assessed daily on a diary card during the course of the
study. There was no intervention to change or improve com-
pliance.
Materials and methods
Patients and treatment
The patients (11 male three female) mean ± s.d. age
62.4 ± 11.0 years were being treated at the out-patient clinic
at the Homerton Hospital. Participation in the study was
limited to those patients receiving low dose oral etoposide for
small-cell lung cancer. Of the 14 patients, nine had received
no prior treatment and were given single-agent etoposide.
One patient had received previous radiotherapy and IV
chemotherapy with etoposide and cisplatin. One patient had
received radiotherapy immediately prior to starting single-
agent etoposide and two patients were receiving combination
chemotherapy with IV cyclophosphamide and vincristine on
day 1 then oral etoposide on days 1-14 of a 21 day cycle.
The low-dose etoposide schedule used was 50 mg twice daily
for 14 days of a 21 day cycle although this was reduced or
modified depending on the toxicity.
Compliance assessment
Compliance with oral etoposide was assessed using an elec-
tronically monitored tablet bottle which is described in detail
elsewhere (Nicholson, 1991). A concealed electronic device in
the container records the time (to the nearest hour) when the
cap is removed. The data are collected for a period of up to 6
weeks and are read-out and processed by computer to give a
list of the date and time of bottle openings and a graphic
representation from which information is available on the
number of doses taken daily, the number of missed or extra
doses and the dosing intervals. We developed (Lee et al.,
1992) three measures to describe compliance patterns
generated by the electronic device which are summarised
here:
Overall Compliance (OC): This is a measure of the totality
of compliance and is obtained by dividing the number of
bottle openings over the whole treatment period by the
number expected had compliance been perfect and is ex-
pressed as a percentage.
Daily Irregularity Index (DII): Although the total number
of openings may be correct (i.e. 100% overall compliance)
there may be deviations from the prescribed daily number.
This index therefore represents the number of daily dis-
crepancies in bottle openings averaged over the treatment
period. A figure of 0 for the index represents no extra or
omitted openings and a figure of 1 represents one extra or
missed opening per day.
Hourly Irregularity Index (HII): Even with the correct
number of openings per day there may be irregularity in the
time of bottle opening. This index therefore, represents the
repeatability of the patient's own hourly pattern of openings.
The modal values of the intervals are first determined for the
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patient and then intervals are scored in relation to the mode
using a sliding scale. The total score for all the intervals
graded is divided by the total number of intervals for the
course. This gives an irregularity index from 0-1 for the
treatment period where 0 corresponds to an exactly repeat-
able hourly pattern of bottle openings.
Assessment ofside-effects and quality oflife
Experience of side-effects and quality of life was self-assessed
daily by patients using a diary card. This was validated
previously and was shown to reflect day to day variation in
symptoms during chemotherapy (Geddes et al., 1990).
Patients responded on a 4 point scale to eight questions. The
questions cover three categories: (a) symptoms related mainly
to treatment - sickness, vomiting and appetite; (b) symptoms
related to disease - pain; and (c) a general assessment -
mood, sleep, activity and general wellbeing. The mean score
for each question was calculated for the treatment period.
Study design
Where possible patients were monitored for two or more
cycles of etoposide, not necessarily consecutively. Informed
consent for monitoring the effects of the treatment was
sought but patients were not told the recording nature of the
bottle. Patients were told that the intention was to make a
detailed assessment of symptoms using a diary card; if they
asked what the bottle was they were told that it had a light
proof construction. If more details about the device were
requested consent was obtained to reveal this at the end of
the study. This applied to two patients out of the 14. The
study was approved by the ethical committee of the hospital.
The diary card was given out by the research pharmacist
and the patient was shown how to complete it at the end of
each day. The patient's prescription and the electronic tablet
bottle were taken to the hospital pharmacy department. The
prescription was dispensed in the normal manner, clearly
labelled as to the contents and treatment regimen with the
exact number of capsules required. Patients were asked not
to transfer the capsules to any other container and to return
the containers and completed diary card next time they
attend the clinic. On returning the containers any remaining
capsules were counted. A record of attendance at the clinic
was kept.
Statistical methods
The relationship between each of the three compliance
measures and the various explanatory measures was
examined by a linear modelling approach using the statistical
package GLIM (GLIM 3.77, 1978) as described previously
(Lee et al., 1992). This allows for the testing of possible
effects both within patients and between patients. Of the
explanatory measures the monitoring period sequence (i.e.
whether the 1st, 2nd or third period of monitoring) was
regarded as a factor and the other measures, the eight diary
card scores and the time since initial diagnosis were regarded
as continuous variables. Each of the ten explanatory
measures was alternatively entered into the equation and its
effect tested for significance. If it reached P <0.05 the
measure was retained in the equation. The process was then
repeated with all the other measures, but in fact with the
present data set, no effect of any second explanatory measure
reached significance. The residuals were tested for normal
distribution by the Shapiro-Francia W' test (Royston, 1983).
In the case of the OC the residuals were initially found to
depart marginally from normality and so to correct this the
OC was transformed by the expression
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This transformation acts symmetrically on OC values either
side of the 100% value and has negligible effect (apart from a
change of scale and shift of origin) for the majority of values
which lie near the 100% value, but acts to shift the more
outlying values nearer the 100% value.
Results
No patient refused to partipate in the study, however two
patients failed to return their tablet bottles at their next
appointment and due to rapid deterioration of their disease
had no subsequent out-patient appointments so no data were
available from them. Patients received the exact number of
capsules required for their course of treatment so none
should have been returned. On no occasion were any cap-
sules found remaining. No patient failed to attend for
scheduled clinic appointments except when they became pro-
gressively ill, when alternative arrangements were made.
Analysis ofrecords
A total of 25 treatment periods were analysed from 12
patients who were all unaware that monitoring was taking
place. These patients were monitored for one to three cycles
(mean 2.1). Of the 25 treatment periods 20 were for 50mg
etopside twice daily, three were for 50 mg twice daily alter-
nating with 50 mg once daily and two were for 50 mg once
daily.
Figure 1 shows the distribution of dosage intervals from all
twice daily regimens. Figures 2, 3 and 4 show the distribution
of the three measures of compliance for all the treatment
periods, representing monitoring over 298 days. For the OC,
DII and HII over the 25 treatment periods the mean (± s.d.)
values were 93.2% (± 12%), 0.19 (± 0.13) and 0.29 ( 0.17)
respectively. The DII and HII were positively correlated
(R = 0.78, D.F. = 23, P <0.001) but the OC showed no
significant association with either the DII or the HII
(P>0.05 in both cases).
No significant (at P = 0.05) effect of monitoring period
sequence was found on any of the three compliance
measures. A significant within-patient effect on the OC was
found on the diary card scores for sickness, vomiting,
appetite, pain and activity, the most variance being explained
by the activity score (P <0.005). However it was apparent
that all these explanatory variables were inter-related,
because if the activity score were already entered into the
equation, the addition of any of the other three scores did
not make a significant contribution. The effect of the activity
score was in the positive direction and corresponded to a
decrease in OC of about 3% with a decrease in the activity
score of one.
On the DII none of the diary card variables showed a
significant effect. There was a between-patient effect
(P <0.025) on the DII of the time since diagnosis, and this
corresponded to a decrease in the DII of 0.005 per month.
On the HII there was a between-patient effect (P <0.025) of
the score for vomiting, and this corresponded to an increase
in the HII of 0.24 for an increase in the vomiting score of
one.
It is of interest to compare the compliance measures with
the previously observed in lymphoma patients (Lee et al.,
1992). The latter group of patients were prescribed a wide
range of dose frequencies compared to the present group. As
dosage frequency was previously shown to affect compliance,
for the purposes of comparison only data relating to drugs
prescribed twice a day was used. Because, in both groups,
individual patients were followed for differing numbers of
treatment periods the mean values for the three compliance
measures over all treatment periods for each patient were
first calculated, and then the mean and s.d. of these (i.e.
between patients) were calculated. For the present group (ten
patients) the resulting mean (± s.d.) values for the OC, DII,
and HII were 94.7% (± 6.7%), 0.22 (± 0.11) and 0.31
(± 0.14) respectively and for the lymphoma group (11
patients) they were 96.4% (± 8.9%), 0.11 (± 0.09) and 0.31
(± 0.18) respectively. Comparison of these values for signifi-
cant differences by unpaired t test showed that only the DII632 C.R. LEE et al.
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Figure 1 Distribution of dosage intervals from all twice daily regimens.
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Figure 2 Distribution of overall compliance of 25 treatment periods.
in the present group differed from that in the lymphoma
group (t = 2.46, d.f. = 19, P <0.05).
The eight scores for physical and mental state of the
patients in the present group were assessed in the same way
as done previously in lymphoma patients so a direct com-
parison is possible. Because the patients were followed for
differing numbers of treatment periods the mean value over
all treatment periods for each patient for each of the eight
scores was calculated. For the lymphoma group all patients
were included regardless of treatment. The mean values
(± s.d. between patient) for the present group (12 patients)
and the lymphoma group (18 patients) are given in Table I.
Comparison of the means by unpaired t test showed that the
score for activity was significantly lower in the present group
(t = 2.8, d.f. = 28, P <0.01).
Discussion
Our previous report (Lee et al., 1992) using the same
methodology on lymphoma patients showed compliance
levels which were very encouraging. The results reported here
are equally encouraging even though the patients had a less
optimistic clinical outlook. Because our patients were aware
that they were part of a study ostensibly assessing the side
effects of treatment, the possibility cannot be excluded thatPATIENT COMPLIANCE WITH ORAL ETOPOSIDE 633
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Table I Mean values of the diary card scores for the two groups of
patients
SCLC Lymphoma
(12 patients) (18 patients)
Mean s.d. Mean s.d.
Sickness 1.35 0.35 1.25 0.44
Vomiting 1.18 0.30 1.17 0.41
Appetite 1.75 0.58 1.49 0.52
Pain 1.30 0.35 1.46 0.56
Sleep 1.75 0.46 2.04 0.56
Activity 2.44a 0.53 3.07a 0.70
Mood 1.71 0.50 1.55 0.51
General wellbeing 1.72 0.55 0.76 0.55
aDifference significant P <0.01.
this may have influenced their compliance. However as they
were unaware that compliance monitoring was taking place
we feel that the magnitude of any such effect would be small.
When comparing the scores for mental and physical state
of the present group with the lymphoma group reported
previously the only significant difference we could uncover
was between the scores for activity (P <0.01), it being lower
in the present group. Conventionally etoposide has the
reputation of causing more unpleasant side effects than the
treatments used for lymphoma and this is certainly the case
for alopecia. However we saw no evidence of increased sick-
ness or vomiting. This is in agreement with the suggestion
(Carney, 1991) that the low dose etoposide is better tolerated
than conventional etoposide regimes.
In the relationship of the compliance measures to the
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various explanatory variables, a decrease in OC with a
decrease in activity score was seen (P <0.001), an increase in
DII with increase in time since diagnosis (P <0.025), and an
increase in HII with the vomiting score P <0.025). All these
effects are small in magnitude and seem likely to have negli-
gible practical consequences. It is interesting however that, of
the diary card measures, the activity score, as well as being
the only distinguishing feature between the present group and
the lymphoma group, has also a highly significant effect
(even if small in magnitude) on overall compliance in the
present group.
As noted in our previous study (Lee et al., 1992), the
differing degrees of compliance seen our work, and that of
earlier studies (Levine et al., 1987; Lebovits et al., 1990), may
stem from several sources. The methods employed in these
latter studies for measuring and scoring compliance were
different, and variations in medical practice between coun-
tries may account for some difference. Nevertheless the high
levels ofcompliance observed in our studies imply that inade-
quate compliance is unlikely to be a significant factor
affecting treatment outcome in these groups of patients. The
high compliance may be seen as in line with the readiness of
cancer patients to opt for radical treatment with minimal
chance of benefit, as documented by Slevin et al. (1990). This
inspires confidence in the use of the self-administered oral
medication which has advantages in the cost of treatment
and convenience for the patient.
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